Deoxynucleoside analogues such as 5-aza-2-deoxycytidine (depicted by Z) are converted into the triphosphate inside S-phase cells and are incorporated in place of cytosine into DNA. Ribonucleosides ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man’s risk of being diagnosed with prostate cancer from around 5–9% to around 4-6% during up to 7 years of ...

This article presents background information and highlights key findings from a managed care perspective related to enlarged prostate (EP) in Medicare-eligible patients. This article does not provide ...

Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer. Background: AA, a selective androgen biosynthesis inhibitor, blocks the action of CYP17, thereby ...

Objective: The purpose of this study was to examine the rates of acute urinary retention (AUR) and surgery after initiating 5-alpha reductase inhibitor (5ARI) therapy and to compare the 2 currently ...

A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors. Men with continuous use of 5-alpha reductase inhibitors ...

It is important for urologists and primary care physicians to be aware of the potential link between BPH medications and heart failure risk, according to investigators. Heart failure risk is increased ...

Mevinolin in the hydroxy acid form, mevinolinic acid, is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [mevalonate: NADP + oxidoreductase (CoA-acylating), EC ...